GoKawiilAntisense RNA therapy shows early promise in rare ALS case, plus US sanctions linked to Chinese patent surge
An antisense oligonucleotide therapy targeting the faulty CHCHD10 gene produced improved symptoms in the first ALS patient treated with it, who remained functional as a physician a year later. Separately, a study found that Chinese companies placed on the US Entity List appear to have increased their science patents and publications compared with non-sanctioned firms, though causation remains unproven.
GoKawiil's interpretation of the reporting above, not reported fact.
The ALS case offers a glimpse of how gene-targeted RNA drugs could eventually help the small share of patients with identifiable genetic mutations, and potentially other rare neurodegenerative diseases. The sanctions finding complicates the assumption that export controls simply slow down targeted firms, suggesting policymakers should weigh possible unintended boosts to innovation against the intended restrictions.
- A CHCHD10-targeting antisense therapy showed sustained clinical improvement in its first ALS recipient after one year.
- Only 5-10% of ALS cases have known genetic mutations, limiting but not eliminating the therapy's potential reach.
- Companies on the US Entity List showed more patents and papers than unsanctioned peers, raising questions about sanctions' side effects.
Source: nature.com — Graham, 2026-09-18
Published there as: “Daily briefing: How to turn a paper into an AI agent”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.